Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
COMPASS Pathways heads into its November 5 earnings date with short sellers quietly adding pressure and the stock nursing a 12% loss over the past month, even as the COMP360 regulatory story remains intact.
Short interest has crept higher in a way that deserves attention. Estimated short shares have risen roughly 10.8% over the past month and 3.4% over the past week, reaching around 15.1 million shares. The ORTEX short score has climbed to 68.6 from 61.5 ten days ago, its highest reading in the recent window. The direction of travel is clear: bearish positioning has been building steadily since mid-September. Borrow costs remain very low at 0.59%, up 17% on the week but still nowhere near punishing. What has changed sharply is availability: it has tightened from above 400% in late September to 239% this week, a 41% drop in seven days. That still represents ample supply relative to the shares already borrowed, so there is no squeeze mechanics in play yet. But the tightening pace is worth watching. The short score ranks in just the 14th percentile of the universe on a short-score basis, which reflects a material, if not extreme, bearish lean.
The Street's view on CMPS is broadly constructive but fractured on conviction. Most recent analyst data is from early August, so it should be treated with caution given the 62-day lag. Morgan Stanley maintained its Overweight rating and lifted its target to $18, while RBC held Outperform at $21 and B. Riley moved its target up sharply to $22. Wells Fargo initiated at Equal-Weight with a $13 target in late July, a level that sits close to where the stock is now trading at $11.69. HC Wainwright holds a $65 target, but that outlier looks inconsistent with the cluster of targets in the $18 to $22 range and may reflect different modelling assumptions. The mean analyst target of $23.75 implies substantial return potential from current prices, but with the stock well below where most analysts expected it to be, the gap between consensus and price is doing most of the talking. Factor scores lean positive on earnings quality: the EPS surprise rank is in the 97th percentile and the 90-day EPS momentum ranks 93rd. The bear case centres on cash burn, regulatory execution risk, and competitive pressure in the treatment-resistant depression space, with the company's $433 million cash runway into 2028 providing a floor but not a catalyst.
The activist register carries a note worth flagging. ATAI Life Sciences, which filed a Schedule 13D amendment in October 2025, has trimmed its stake from 7.5% to 6.0% as last disclosed. A separate 13D filer, AtaiBeckley Inc., reported 4.96% in February 2026. Both filings are 13D, meaning the SEC register carries an activist designation for these holders. As always, these positions are as-last-disclosed around the 5% threshold, and either holder could have moved further without filing again. Among institutional holders, BIT Capital added nearly 2.9 million shares in the last reported quarter to bring its position to 6.3 million shares, and Tang Capital added roughly 1 million shares to reach 5 million. ARK Investment Management, whose holdings are current to September 30, added 1.2 million shares during the quarter. The net picture from the holder register is one of selective accumulation rather than broad distribution.
Earnings history gives some useful context ahead of the November 5 report. The August 2026 print produced a 14.8% one-day gain and a 20.5% five-day gain. The prior report in July 2026 moved the stock 4.1% on day one and 24.3% over five days. The pattern, though a small sample, points to material post-earnings moves to the upside in recent quarters, which may explain why the options market remains skewed toward calls: the put/call ratio is 0.25, close to the low end of its 52-week range of 0.12 to 1.38, and only slightly above its 20-day average of 0.23. Options traders are not defensively positioned ahead of the print.
The next four weeks will turn on two threads: whether the rolling NDA submission stays on track for all remaining modules in the fourth quarter, and whether the short-interest build that accelerated through September reflects a fundamental reassessment or simply momentum selling into a weaker tape.
See the live data behind this article on ORTEX.
Open CMPS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
